Envestnet Asset Management Inc. Has $29.94 Million Stock Position in Illumina, Inc. $ILMN

Envestnet Asset Management Inc. lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 315,264 shares of the life sciences company’s stock after buying an additional 8,621 shares during the quarter. Envestnet Asset Management Inc. owned about 0.21% of Illumina worth $29,941,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Parkside Financial Bank & Trust increased its holdings in shares of Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 115 shares in the last quarter. Quent Capital LLC bought a new position in shares of Illumina in the 3rd quarter worth $29,000. Cullen Frost Bankers Inc. acquired a new stake in Illumina in the 2nd quarter valued at $41,000. NewSquare Capital LLC grew its position in Illumina by 604.9% in the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after purchasing an additional 369 shares during the period. Finally, Mather Group LLC. bought a new stake in Illumina during the 3rd quarter valued at $46,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ILMN shares. Canaccord Genuity Group boosted their target price on shares of Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, January 26th. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Barclays raised their target price on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a report on Monday, December 15th. Evercore ISI set a $150.00 price target on Illumina in a report on Friday, February 6th. Finally, Guggenheim raised their price objective on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Six investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $129.17.

Insiders Place Their Bets

In related news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 2.60% of the stock is owned by insiders.

Illumina Stock Performance

Shares of ILMN stock opened at $114.44 on Friday. The firm’s 50 day moving average is $137.54 and its 200 day moving average is $116.47. The stock has a market capitalization of $17.49 billion, a P/E ratio of 21.00, a PEG ratio of 2.23 and a beta of 1.45. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $155.53. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.26 by $0.09. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.